Clinical features of CLL patients by FcγRIIa polymorphism type
. | FcγR H/H, n = 6 . | FcγR H/R, n = 17 . | FcγR R/R, n = 7 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 68 (51-80) | 57 (50-79) | 74 (64-79) | .03 |
| No. male (%) | 5 (83) | 11 (65) | 7 (100) | .16 |
| Median WBC count, ×109/L (range) | 39.3 (3.4-154.8) | 84.5 (4.8-175.3) | 44.8 (2.5-173.4) | .59 |
| No. stage III/IV (%) | 3 (50) | 13 (77) | 6 (86) | .32 |
| Mean prior regimens (range) | 3 (1-6) | 2 (0-6) | 2 (0-4) | .67 |
| No. prior nucleoside analog treatments (%) | 3 (50) | 10 (59) | 4 (57) | .93 |
| No. with lymphadenopathy (%) | 5 (83) | 16 (94) | 7 (100) | .48 |
| No. infusion toxicity (%) | 2 (33) | 6 (35) | 4 (57) | .57 |
| No. partial responses (95% CI) | 4.67 (22-96) | 5.29 (10-56) | 4.57 (18-90) | .70 |
. | FcγR H/H, n = 6 . | FcγR H/R, n = 17 . | FcγR R/R, n = 7 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 68 (51-80) | 57 (50-79) | 74 (64-79) | .03 |
| No. male (%) | 5 (83) | 11 (65) | 7 (100) | .16 |
| Median WBC count, ×109/L (range) | 39.3 (3.4-154.8) | 84.5 (4.8-175.3) | 44.8 (2.5-173.4) | .59 |
| No. stage III/IV (%) | 3 (50) | 13 (77) | 6 (86) | .32 |
| Mean prior regimens (range) | 3 (1-6) | 2 (0-6) | 2 (0-4) | .67 |
| No. prior nucleoside analog treatments (%) | 3 (50) | 10 (59) | 4 (57) | .93 |
| No. with lymphadenopathy (%) | 5 (83) | 16 (94) | 7 (100) | .48 |
| No. infusion toxicity (%) | 2 (33) | 6 (35) | 4 (57) | .57 |
| No. partial responses (95% CI) | 4.67 (22-96) | 5.29 (10-56) | 4.57 (18-90) | .70 |